Access to Medicine Index 2022 ▶ Company report cards

RA N KSCO R E

15

2.60

19 (2021)*

Bristol Myers Squibb
Stock exchange: NYSC • Ticker: BMY • HQ: New York, United States • Employees: 32,200

PERFORMANCE IN THE 2022 INDEX
15th place. Bristol Myers Squibb performs below average in
two of three Technical Areas. The company has performed
below average for access strategies, yet it performs strongly
in health systems strengthening. It has improved in accessHow score was achieved
3.86

Governance of Access
1.80

Research & Development

2.69

Product Delivery

planning in R&D but has a small-sized priority pipeline.

01

Governance of Access: 14th place. Bristol Myers Squibb has

2

3

Average

Leader4

5

an average performance in this area. It has an access-to-medicine strategy integrated within the overall corporate strategy.
It provides evidence of financial and non-financial access-re-

Product Delivery: 15th place. Bristol Myers Squibb has a below

lated incentives at the executive level but does not disclose

average performance in this area. The company has strength-

whether in-country managers or the CEO are also incentiv-

ened its performance in manufacturing capacity building byised toward access goals.

participating in technology transfers, yet its performance inequitable access strategies is below average for certain prod-

Research & Development: 17th place. Bristol Myers Squibb

ucts. It engages in high quality health systems strengthen-performs poorly in this area. The company has a structured

ing initiatives but lacks involvement in supply chain capac-

access planning process in place, but it does not apply this toity building. The company has non-exclusive voluntary licens-all late-stage candidates. The company has an average perfor-

ing agreements in place for two compounds to enable genericmance in R&D capacity building.

supply in LMICs.

OPPORTUNITIES FOR BRISTOL MYERS SQUIBBCHANGES SINCE THE 2021 INDEX

Develop access-related incentives for senior management. Bristol Myers Squibb has• Launched the first ever Global Access Report, which

an access strategy linked to sustainability goals, which includes all therapeutic areas inhighlights Bristol Myers Squibb’ efforts and progress

which the company is involved. Financial and non-financial incentives for the CEO andtowards advancing access to healthcare and health equity

in-country managers can be tied to the achievement of the sustainability goals underglobally.

their access strategy. The incentives can also be oriented toward long-term goals.

• Newly demonstrates evidence that sales agent incentives

Ensure all late-stage R&D projects have comprehensive access plans. Bristol Myers• Introduced a structured framework to include accessare decoupled from sales volume targets.
Squibb can develop access plans for all projects from Phase II of clinical development.
The company has plans in place for 73% of late-stage projects. These plans primarily

planning in all its pipeline projects.
• Started a new capacity building initiative with multiple

consist of commitments to registering products in countries where clinical trials for thatpartners to support sustainable and effective administration

product have been conducted. Access plans for nivolumab (Opdivo®) and pomalidomide

of innovative therapies for the treatment of cancer in(Pomalyst®), indicated for multiple cancer types, can also include additional accesscomponents such as equitable pricing.

LMICs.
• Newly licensed the >4000-member library to Medicinesfor Malaria Venture (MMV) in addition to donating USD 1

Improve access to on-patent cancer drugs on WHO Model List of Essential Medicines(EML). Bristol Myers Squibb has four on-patent products on the WHO EML, including
dasatinib (Sprycel®), a product indicated for imatinib-resistant chronic myeloid

million to support the missions of both MMV and Drugs for
Neglected Diseases initiative (DNDi).
• Joined the Access to Oncology Medicines (ATOM) Coalition,

leukaemia. The company provides access to dasatinib in at least one upper-middle
income country via an equitable pricing strategy and to low-income countries and lower-a new global initiative that aims to improve access toessential cancer medicines in LMICs.

middle income countries via the Max Foundation donation programme. Bristol Myers• Acquired a global exclusive license to develop, manufacture

Squibb can expand access to the product via registration, equitable pricing and non-and commercialise Rockefeller’s novel monoclonal antibody

exclusive voluntary licensing agreements in more countries, especially those where theduo treatment against COVID-19.

burden of disease is the highest, such as Afghanistan, Haiti and Ethiopia.

21

All companies were assessed based on
information that was valid in the latest
period of analysis (ending at 31 May2022). This data was either submitted bycompanies, found in the public domain or
was accessible through other sources.

The term LMICs is used to denote all
low- and middle-income countries inscope of the Index, except when analysing
companies’ access strategies where
the use of LMIC refers to lower-middle
income countries as per the World Bank

income groups classification. Likewise, theterms LIC and UMIC refer to low income
countries and upper-middle income
countries.
*In the 2021 Index, dense ranking wasused. In the 2022 Index, standard

competitive ranking is used. Therefore,
a direct comparison with Bristol Myers
Squibb's previous rank is not possible.

Access to Medicine Index 2022 ▶ Company report cards

SALES AND OPERATIONSBusiness segments: Pharmaceutical.

Bristol Myers Squibb's products are sold in

Therapeutic areas: Cardiovascular disease,38 out of 108 countries in scope of the Index.

Revenue by segment (2021) – in USD

fibrotic disease, haematology, immunology andBristol Myers Squibb has sales offices in 7

Pharmaceuticaloncology.

countries, and sells via suppliers and/or pooled		Product categories: Innovative medicines.

procurement in an additional 31 countries.

Total

46.39 bn
46.39 bn

M&A news: Bristol Myers Squibb acquired
Turning Point Therapeutics in June 2022 for
USD 76.00 per share.

Sales by geographic region
50

Revenue (Bn USD)

Sales in countries in scope

40
30
20
10
0

In scope, has sales offices
In scope, any sales

2017

2018

Rest of WorldIn scope, no sales

2019

2020

Europe

USA

2021

Other

Not in scope

SAMPLE OF PIPELINE AND PORTFOLIO ASSESSED BY THE INDEXPIPELINE for diseases in scope

PORTFOLIO as selected for analysis by the Index

Bristol Myers Squibb has a total of 53 R&D projects in scope with one pro-

Bristol Myers Squibb has 15 medicines in scope, 12 of which are on patent.

ject targeting a priority disease. This project targets COVID-19. The other

33% of these medicines (5) are on the WHO EML. The off-patent medicines

52 R&D projects target other diseases in scope. These projects mainly

target mainly non-communicable diseases such as cancer (2) and thalas-

focus on oncology (47 projects).

saemia (1). The on-patent medicines mainly target cancer (9), HIV/AIDS (2)Eleven R&D projects are in late-stage development that target either a pri-and viral hepatitis C (1).

ority disease (1) or address a public health need in LMICs (10).* Evidenceof access planning was in place for 73% of these projects: none targeting apriority disease and eight addressing a public health need in LMICs.

53 projects in the pipeline

15 products as selected for analysis by the Index†

Communicable** 1

Communicable**

Neglected tropical 0

Neglected tropical 0Maternal and neonatal 0

Maternal and neonatal 052

Non-communicableMultiple categories 0
0

40
60
80
100
projects in the pipeline

10

20
30
40
50
products on the market

0

0

1

0

0

0

1

Contraceptives

Addresses needs of LMICs*

4

3

5

2

0 14

Diagnostics

Other projects in scope

25 10

2

1

0 38

Other

*50 diseases and 243 product gaps inscope have been established as a priority by global health stakeholders. For
other diseases, the Index used a set of criteria to determine which projects in thepipeline offer a clear public health benefit to patients in LMICs. Only projects inthe clinical phase of development were
included for this analysis.
**Neglected tropical diseases, while also
communicable, are highlighted separately
throughout the Index.
***Other includes projects that have atechnical lifecycle and projects that fol-

‡

Total

0

Targets established R&D priorities

Other

0

Vaccines

WHO EDL

0

Total

0

Other***

0Registration/approval

30Phase III2

Phase II

8

1

Phase I4

off patent

Pre-clinical

Medicines on patent

Discovery

Non-EML

Breakdown of products
WHO EML

20

Breakdown of projects

2212

Non-communicableMultiple categories 0
0

3

12

0
0

0
0

low a different development cycle (e.g.
diagnostics).
†Products included in the analysis wereselected using a set of criteria determinedby stakeholder consensus.
‡Other includes vector control products.

0

Access to Medicine Index 2022 ▶ Company report cards

Bristol Myers Squibb

GOVERNANCE OF ACCESSRANK 14SCORE 3.86

Has an access-to-medicine strategy with meas-

ble goals, objectives and sustainability targets,

the Index: fraud-specific risk assessment, coun-urable objectives. Bristol Myers Squibb performs

including enhancing patient access to medi-

try risk-based assessment, a continuous systemstrongly. Its strategy is fully integrated withincines. It facilitates accountability and transparency

to monitor activities, audits (both internal andthe overall corporate strategy and covers all ofby consistently sharing the outcomes of its

external, covering third parties and in all coun-

the therapeutic areas in which the company isaccess-to-medicine activities in a centralised

tries where it operates) and has formal processes

involved. The highest responsibility for access lies

manner within its Global Access Report.

to ensure compliance with company standards bydirectly with the board, with the Board Chair andthird parties. No breaches in countries in scope

CEO responsible for final decisions regarding the

Performs above average in responsible pro-of the Index were publicly found in the period ofdevelopment of each product's access strategy

motional practices. Bristol Myers Squibb's sales

analysis.

and programs.

agents are not solely incentivised on sales volume. However, the level at which sales targets are

Does not publicly support the Doha Declaration

Provides evidence of financial and non-financial

set varies at the individual, team, business unit,

on TRIPS and Public Health. Bristol Myers

access-related incentives at the executive level.

national and global level, as well as by therapeu-

Squibb does not publicly share any support of theBristol Myers Squibb performs below average. It

tic area. It publicly discloses information related

Doha Declaration on TRIPS and Public Health.

incentivises its senior executives to take action

to transfers of value to healthcare professionals

There is evidence of industry association lob-on access to medicine with financial and non-fi-

in countries in scope of the Index (e.g., payments

bying on IP and the usage of TRIPS flexibilities,

nancial rewards. It does not disclose, however,for attending events or promotional activities) in

namely of compulsory licensing, by national gov-

whether in-country managers or the CEO are also

accordance with laws and regulations.

ernments in some countries in scope of the Index.

incentivised toward access goals.

As a member of the industry association, Bristol
Has a robust set of compliance controls to

Myers Squibb, like all other member companies

Publicly discloses outcomes its access-to-med-ensure that governance efforts are not under-in scope of the Index, is by default connected toicine activities. Bristol Myers Squibb performs

mined by non-compliant or corrupt activities.

this activity.

strongly in transparency of access activities.

Bristol Myers Squibb performs strongly, demon-

It publicly discloses commitments, measura-strating evidence of all components looked for by

RESEARCH & DEVELOPMENTRANK 17SCORE 1.80

Access planning processes encompass all pro-

Bristol Myers Squibb has ten late-stage R&D pro-

One R&D capacity building initiative included

jects in the pipeline. Bristol Myers Squibb has

jects that target a disease and/or product gap

for analysis meets all Good Practice Standards.

a structured process in place to develop accessnot yet established as a priority by global healthBristol Myers Squibb's performance is averageplans during R&D. The process is intended to

stakeholders. These projects are all deemed byin this area. The number of initiatives meet-

be applied to all R&D projects (both in-house

the Index to offer a clear public health benefit

ing all inclusion criteria is lower than averageand collaborative) for diseases in scope of thefor people living in LMICs.* Primarily, these pro-and fewer initiatives meet all Good PracticeIndex. The phase at which access planning begins

jects concern clinical trials in countries in scopeStandards than what is average for this indicator.

depends on the product.

of the Index and/or are first-in-class molecules.

Bristol Myers Squibb supports the sustaina-

Most target cancer. These plans primarily relate

ble and effective administration of innovative

A small-sized priority R&D pipeline comparedto Bristol Myers Squibb's commitment to register

therapies for the treatment of cancer in LMICs

to its peers, with no access plans in place.

in the countries where it is carrying out clinical tri-

through its Innovative Cancer Medicines (ICM)

Bristol Myers Squibb has one late-stage candi-als. Therefore, plans for registration in countries

partnership with the Parker Institute for Cancer

date in its pipeline that targets a priority productwithin scope of the Index apply to eight pipeline

Immunotherapy and the Clinton Health Accessgap. This is the clinical development of abata-projects.

Initiative.

cept (Orencia®) to treat COVID-19. Bristol Myers
Squibb did not submit evidence of an access plan

Does not publicly disclose R&D investment

for this project.

data disaggregated by disease category, product type or phase of development. Bristol Myers

Some projects address a public health need

Squibb does not disclose disaggregated R&D

in LMICs,* with 80% (8/10) of late-stage pro-investment data to global health organisations.

jects covered by access plans. In this analysis,

23*50 diseases and 243 product gaps inscope have been established as a priority
by global health stakeholders. For otherdiseases, the Index used a set of criteria
to determine which projects in the pipeline offer a clear public health benefit topatients in LMICs. Projects in the clinicalphase of development were included forthis analysis.

Access to Medicine Index 2022 ▶ Company report cards

PRODUCT DELIVERYRANK 15SCORE 2.69

No public commitment not to enforce pat-country non-eligible to benefit from The Globalof the leaders in this area. The number of ini-

ents in countries in scope. Bristol Myers Squibb

Fund supranational procurement agreement.

tiatives meeting all inclusion criteria is higher

does not have a public commitment not to

The company provides evidence of patient reach,than average and more initiatives meet all Good

file or enforce patents in LMICs. Bristol Myers

reporting that through the MPP license, 2.1 million

Practice Standards than what is average for thisSquibb commits to ensure that its patents dopatients per year were reached.

indicator. For example, the company collabo-

not prevent inexpensive HIV/AIDS therapy inrates with University Research Co. (URC) on the

resource-constrained countries and regions such

Has few access strategies for its health-Multinational Lung Cancer Control Program — a

as sub-Saharan Africa and India.

care practitioner-administered products inlung cancer programme implemented in sevenscope of this analysis. Bristol Myers Squibb

countries to improve access to early diagnosis by

Publicly discloses information on patent sta-

performs below average in this area. It pro-addressing barriers to care.

tus. Like most of its peers, Bristol Myers Squibb

vides evidence of access strategies in UMICs anddiscloses the patent statuses for small molecules

LMICs for three products assessed. For example,

Has no inclusive business models that meetin scope via the Pat-INFORMED database. Bristol

in China, it ensured the inclusion of two can-all inclusion criteria. There is no evidence that

Myers Squibb discloses this information also incer drugs nivolumab (Opdivo®) and ipilimumab

Bristol Myers Squibb has engaged in the piloting

other websites regarding a subset of products.

(Yervoy®) on private insurance lists. To maxim-

or scale-up of any inclusive business models that

ise patient reach, Bristol Myers Squibb works

aim to meet the access needs of populations at

Is an average-performing company in terms ofwith a charity organisation, Cancer Foundation

the base of the income pyramid (including othersharing intellectual property (IP) assets withof China, to implement a patient assistance pro-

underserved populations) in LMICs. Bristol Myers

third-party researchers. Bristol Myers Squibb

gramme whereby Bristol Myers Squibb shares

Squibb performs below average in this area.

engaged in one new IP-sharing agreement withthe medicines' costs with the patient. Evidence

third-party research institutions or drug discoveryof an increase in patient reach through theseShows average performance in terms of ensur-

initiatives established during the current analysis

approaches is available.

ing continuous supply of medicines in LMICs.

period that meets all inclusion criteria for evalua-

Bristol Myers Squibb manages a buffer stock oftion. The company does have existing agreements

Has few access strategies for its self-admin-

relevant products, is involved in technology trans-of this nature in place that were establishedistered products for some countries in scopefers to local manufacturers in LMICs, and shows

before the current period of analysis and meet allof this analysis. Bristol Myers Squibb performs

evidence of working with stakeholders to com-

inclusion criteria for evaluation.

below average in this area. It provides evidence

municate issues that may impact the supplyof access strategies in countries of all assessed

chain. The company does not show evidence ofUses licensing to enable generic supply. Bristol

income levels (UMIC, LMIC, LIC) for one of theefforts to work with multiple active pharmaceuti-

Myers Squibb has non-exclusive voluntary licens-

two products assessed, dasatinib (Sprycel®), an

cal ingredient suppliers or engage in supply chain

ing agreements in place for two compounds (foroncology medicine. Bristol Myers Squibb demon-

capacity building initiatives that meet inclusion

the diseases in scope). Its broadest licence, forstrated to consider relevant payers' ability tocriteria for evaluation.

atazanavir sulfate (Reyataz®), encompasses 97

pay by securing public reimbursement of dasat-

countries within the scope of the Index, including

inib and lenalidomide (Revlimid®) in Mexico and

Has a policy for reporting substandard and fal-

71 middle-income countries.

Morocco respectively, where public coveragesified (SF) medicines in countries in scope ofis approximately 83% and 30% of the popula-

the Index in less than ten days. Bristol Myers

Filed to register new products in four countries

tion. Evidence that demonstrates patient reach

Squibb has a policy for reporting SF medicines toin scope on average. Bristol Myers Squibb did

through these approaches is available.

relevant health authorities within the timeframe

not disclose evidence of filing for registration anyof ten days looked for by the Index. There is noof its new products in more than half of the top

The one manufacturing capacity building ini-

evidence found publicly of a shortened timeframe

ten high burden countries. Among old products,

tiative included for analysis meets all Goodfor reporting cases which only require visual

its most widely filed is lenalidomide (Revlimid),

Practice Standards. Bristol Myers Squibb's per-inspection to be confirmed.

for non-Hodgkin lymphoma, filed for registration

formance is average in this area. The number ofin 20 countries in scope of the Index, including

initiatives meeting all inclusion criteria is lower

Donates in response to expressed need andthree high burden countries (Bolivia, Ecuador andthan average and fewer initiatives meet all Good

monitors delivery. Bristol Myers Squibb hasPeru). Eight out of its ten products analysed have

Practice Standards than what is average for thispublic policies and supply processes in place tobeen filed for registration in one LIC.

indicator. From 2011 until February 2022, theensure ad hoc donations are carried out rapidly incompany was involved in a technology transfer

response to expressed need, and it shows someHas access strategies for its supranationallyagreement to expand access to atazanavir sulfate

evidence of monitoring the delivery of donations.

procured product in scope for this analysis.

(Reyataz®) in Brazil.
Has no long-term donation programmes for

Bristol Myers Squibb has an average performancein securing access for its product procured supra-

No supply chain capacity building initiatives

neglected tropical diseases or malaria thatnationally. The company demonstrates strategies

included for analysis. There is no evidence — inare eligible for analysis under this indicator.

both in countries eligible for supply from suchthe public domain or disclosed to the Index — ofHowever, the company is engaged in anotherprocurers and in at least one non-eligible coun-supply chain capacity building initiatives active

structured donation programme: the Max Accesstry. For example, it provides atazanavir sulfate

during the period of analysis that met inclusion

Solutions programme where it donates dasati-(Reyataz®) at a not-for-profit price through acriteria for evaluation. Bristol Myers Squibb's per-nib (Sprycel®) for leukaemia to 29 countries since

supranational agreement with The Global Fund.

formance is below average in this area.

2017.

Bristol Myers Squibb has also signed a non-vol-24

untary licensing agreement with the Medicine

All five health systems strengthening initi-

Patent Pool (MPP) to facilitate access to 97 coun-

atives included for analysis meet all Good

tries in scope of the Index, including Algeria, a

Practice Standards. Bristol Myers Squibb is one